Skip to main content

Table 2 The incidence of CM and all-cause mortality among CrAg+ and CrAg- persons, and among persons with and without antifungal therapy

From: The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/μL: evidence based on a meta-analysis

 

Number of reported studies

Number of persons

ES (95%CI)

I2

P

Incidence of CM among CrAg + persons

 1.1 Incidence of CM among CrAg+ persons

6

2118

0.03 (0.01, 0.05)

62.3%

0.021

Incidence of CM among persons with and without antifungal therapy

 2.1 Incidence of CM among persons with antifungal therapy

6

1088

0.03 (0.01, 0.06)

57.7%

0.037

 2.2 Incidence of CM among persons without antifungal therapy

4

1092

0.05 (0.02, 0.09)

71.5%

0.015

All-cause mortality in CrAg+ persons

 1.1 All-cause mortality among CrAg+ persons

8

2265

0.14 (0.06, 0.22)

94.5%

0.000

All-cause mortality among persons who with and without antifungal therapy

 2.1 All-cause mortality among persons with antifungal therapy

6

396

0.17 (0.11, 0.24)

58.3%

0.035

 2.2 All-cause mortality among persons without antifungal therapy

4

1092

0.10 (0.01, 0.19)

93.2%

0.000